Q1 2023 EPS Estimates for Oncolytics Biotech Inc. Reduced by HC Wainwright (TSE:ONC)

Oncolytics Biotech Inc. (TSE:ONC – Get Rating) – Equities researchers at HC Wainwright lowered their Q1 2023 earnings estimates for shares of Oncolytics Biotech in a report issued on Tuesday, March 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.08) EPS, FY2023 earnings at ($0.35) EPS, FY2024 earnings at ($0.31) EPS, FY2025 earnings at ($0.28) EPS and FY2026 earnings at ($0.06) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a C$9.00 price target on shares of Oncolytics Biotech in a research note on Monday, March 6th.

Oncolytics Biotech Stock Up 8.8 %

Shares of TSE:ONC opened at C$1.97 on Thursday. Oncolytics Biotech has a fifty-two week low of C$1.06 and a fifty-two week high of C$3.10. The firm’s 50 day moving average price is C$2.22 and its 200 day moving average price is C$2.07. The company has a quick ratio of 8.86, a current ratio of 9.05 and a debt-to-equity ratio of 1.41. The stock has a market cap of C$116.29 million, a price-to-earnings ratio of -4.48 and a beta of 1.70.

About Oncolytics Biotech

(Get Rating)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.